Do you see GLPs as a therapy or as a platform for the future of healthcare
In 2025, the company reported a modest +0.99% YoY revenue growth, but the underlying story is more interesting: Dupixent ($17.8B) remains the clear growth engine, benefiting from expanding indications like COPD and broader patient reach, while the EYLEA franchise ($7.89B) continues to be a core contributor despite facing biosimilar pressure, supported by the transition to EYLEA HD, and Libtayo ($1.45B) is steadily gaining ground in oncology, particularly in lung cancer settings
"There is no standardization of the dosing, no standardization of safetyand there have been FDA reports of people ending up in the emergency room because of it." Patients should know exactly what they are being prescribed and whether it is FDA-approved
This practice exists because of medical and ethical concerns, leaving us with no solid evidence from clinical trials about how GLP-1 drugs might affect babies through breast milk
When Refunds May Be Issued According to altRx, refunds may be issued in two specific circumstances: Medical ineligibility: A full refund may be issued if a clinician determines during the initial consultation that the patient is not medically eligible for treatment, based on clinical judgment and established medical guidelines
Together, they create a more comprehensive effect than either achieves alone
